Trial Profile

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAY 2927088 (Primary) ; Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms SOHO-02
Sponsors Bayer

10 Mar 2025 Planned End Date changed from 15 May 2028 to 26 Apr 2029.
17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress
05 Sep 2024 According to Bayer Media Release, Trial in Progress (TiP) data from the study will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com